- Fee assured
- Verified this account
- Urological malignancy
I am a leading prostate cancer surgeon with one of the highest caseload for robotic radical prostatectomy in the UK. My NHS practice is at UCLH, the largest robotic pelvic surgery centre in the UK. I pride myself on my very low complication rate. None of the 500 patients on whom I have performed robotic radical prostatectomy as a consultant have needed emergency operations to correct complications of the surgery.
I have a strong track record of leadership and research in prostate cancer. I lead two UK trials designed to investigate ways of improving the lot of men with prostate cancer. I completed the prestigious Royal College of Surgeons Fellowship in robotic surgery and was trained at Cambridge University where I worked for 5 years as a Lecturer.
I pioneer a technique called NeuroSAFE which is designed to increase the possibility of safe nerve sparing, and therefore sexual potency, after robotic radical prostatectomy. I am leading an NHS funded study testing how effective this technique is.
I am known for my work in scrutinising the way prostate cancer is diagnosed and treated and featured in front page UK Broadsheet headlines and National Television News for this work.
I maintain a very low complication rate and blood transfusion rate whilst doing over 4 times the number of robotic radical prostatectomies per year compared to the average UK prostate surgeon. I pride myself on maintaining strong relationships with the patients I treat and many are prepared to talk with people contemplating surgery under my care.
My patients are generally delighted with the care I provide and many are very happy to speak to prospective patients.
I am an expert in robotic surgery. I employ the latest techniques to maximise the quality of life for patients undergoing radical prostatectomy. My approach has been featured in the press. I am an ambassador for Mens Health and my opinion is regularly featured in the press.
Areas of interest
Prostate Cancer Diagnostics, Prostate cancer, Prostate MRI, Prostate biopsy- Transrectal prostate biopsy, Transperineal prostate biopsy, Targetted prostate biopsy, prostate biopsy for prostate cancer; MRI prostate for prostate cancer, Targeted prostate biopsy for prostate cancer, Transperineal prostate biopsy for accurate prostate cancer mapping, Prostatic disease,
Prostate cancer treatment- Robotic prostatectomy, NeuroSAFE, Frozen section , active surveillance, clinical trials, second opinion for prostate cancer options;
Urinary problems- Recurrent urinary tract infection, Lower urinary tract symptoms,
Haematuria, Raised PSA; Urinary/urine symptoms, Chronic prostatitis (CP/CPPS) prostatism, urethral stricture, bladder neck stenosis, TURP, BPH, General Urology, pyelonephritis, Endourology, Kidney stones; ESWL; Urinary stone;
Peno-Scrotal Surgery- Circumcision, Vasectomy, Epididymal Cysts, Hydroceles, Orchidectomy, Orchidopexy, Foreskin problems, Phimosis, Vasectomy, Pain, Lump;
- Nadia Mangra
- The Prostate Centre 32 Wimpole Street London W1G 8GT
- 020 7935 9720
Best poster, BAUS 2016
Best Videoposter, BAUS 2015
Best Paper & Best Poster, BAUS 2013
Best Poster, AUA 2013
First Prize, Best Scientific Abstract & Best poster, EAU 2013
Academy of Medical Sciences grant £29,000 2011
Western Section AUA. Grand Prize Overall Winner, Hawaii. 2006.
“Top Ten” presentation- SIU October 2005.
Young Scientist of the Year Award, International Soc. for Urolithiasis, 2004.
The Inspire Foundation. £35,000 grant 2003
The Tallow Chandlers Award, 1998
(Additional) Languages spoken
- Italian - Conversational
50 peer reviewed articles including:
Apparatus for Histological Validation of Magnetic Resonance Imaging of the Human Prostate. Front. Oncol. 2017
PSA screening improves outcome for men with locally advanced and high risk prostate cancer. Data from the ProtecT trial. European Urology 2017 (In the top 5% of all research outputs scored by Altmetric)
Response of Degarelix treatment in human prostate cancer monitored by HR-MAS1H NMR spectroscopy. Metabolomics (2016)
Evolution and oncological outcomes of a contemporary radical prostatectomy practice in a UK regional tertiary referral centre. BJU Int. 2016 Apr 28.PMID 27124625
The rapid effects of castration on human prostate cancer. Eur Urol. 2015 Nov 10 PMID: 26572708
Intraoperative frozen section of the prostate to reduces the risk of positive margin whilst ensuring nerve sparing Curr Urol. 2016 PMID: 27390582
Choline kinase alpha is an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. J Natl Cancer Inst. 2015 Dec 11;108(5). 2016 May. PMID:26657335
Identification of pathologically insignificant prostate cancer is not accurate in unscreened men. Br J Cancer. 2014 May PMID: 24722183
Multinational, Multi-institutional Study Comparing Positive Surgical Margin Rates Among 22,393 Open, Laparoscopic, and Robot-assisted Radical Prostatectomy Patients. Eur Urol. 2013 Nov 24. PMID: 24290695.
Optimal therapy for high risk localised prostate cancer - should surgery be an option or a preferred primary treatment? BJU Int. 2011 PMID: 21951841
Multi-parametric Magnetic Resonance Imaging to rule-in and rule-out clinically important prostate cancer in men at risk: a cohort study. Urol Int. 2011 PMID: 21701136
Shaw GL and Neal D, Chapter 73 The Prostate and Seminal Vesicles. Bailey and Love’s Short Practice of Surgery 27th Edition. Edward Arnold 2016
Shaw GL. Neal DE. “Molecular Biology of Prostate cancer”, in Tewari A Prostate Cancer: A Comprehensive Perspective Elselvier 2011
Courses offered to GPs
Advanced prostate cancer diagnostics
Improving diagnostic accuracy in prostate cancer.
Robotic surgery for improved outcomes in prostate cancer.
Outcomes (checked and approved by medical professional body)
Please click on this link if you would like to see information about this healthcare professional’s performance compared to their peers, as published by their medical professional body.https://www.baus.org.uk/patients/surgical_outcomes/radical_prostatectomy/surgeon.aspx?id=1409
Performed 150 major robotic cancer operations in 2018
Re-admission rate <1%
Post-operative infection rate <5%
Mortality rate 0%
Patient satisfaction rate >95%
Surgical margin rate less than half national average
- MD Prostate cancer basic research University of London 2006
- MBBS University of London 1999
- FRCS (urol) Royal College of Surgeons 2010
- MRCS Royal College of Surgeons of England 2004
- Fellowship in Robotic surgery Royal College of Surgeons of England 2014
Reference number 4626222
Affiliations / memberships
British Association of Urology
European Association of Urology
Fellow of the Royal College of Surgeons of England
- Highgate Private Hospital, N6 4DJ
- 14:00 - 17:00
- 07954 007540
- King Edward VII's Hospital, W1G 6AA
- 08:30 - 12:30
- 020 7486 4411
- The London Clinic, W1G 6HL
- 08:00 - 12:30
- 020 7935 4444
- The Princess Grace Hospital, W1U 5NY
- 08:00 - 12:30
- 020 3131 2549
- The Prostate Centre, W1G 8GT
- 09:00 - 17:00
- 020 7935 9720
Post treatment communication
Following treatment of a Bupa member, we will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
9-5 Private Secretary (Sam Thornton) 07954 007540. Out of hours contact the hospital where surgery was performed who are able to contact me.